10,509 Shares in Celgene Corporation (CELG) Purchased by Berson & Corrado Investment Advisors LLC

Berson & Corrado Investment Advisors LLC bought a new stake in Celgene Corporation (NASDAQ:CELG) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,509 shares of the biopharmaceutical company’s stock, valued at approximately $1,365,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. State Street Corp increased its stake in Celgene Corporation by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after acquiring an additional 723,844 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Celgene Corporation by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock valued at $1,255,309,000 after acquiring an additional 472,067 shares during the last quarter. American Century Companies Inc. increased its stake in Celgene Corporation by 4.4% in the first quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock valued at $816,733,000 after acquiring an additional 276,089 shares during the last quarter. Pioneer Investment Management Inc. increased its stake in Celgene Corporation by 15.7% in the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock valued at $650,911,000 after acquiring an additional 710,584 shares during the last quarter. Finally, Clearbridge Investments LLC increased its stake in Celgene Corporation by 24.1% in the first quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock valued at $572,617,000 after acquiring an additional 892,392 shares during the last quarter. 79.43% of the stock is currently owned by institutional investors and hedge funds.

In related news, Director Michael D. Casey sold 9,250 shares of the business’s stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $125.59, for a total transaction of $1,161,707.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Robert J. Hugin sold 175,970 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the transaction, the insider now owns 1,033,909 shares of the company’s stock, valued at approximately $138,688,553.26. The disclosure for this sale can be found here. In the last quarter, insiders have sold 267,476 shares of company stock valued at $35,812,841. 0.95% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “10,509 Shares in Celgene Corporation (CELG) Purchased by Berson & Corrado Investment Advisors LLC” was first posted by Equities Focus and is the property of of Equities Focus. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.equitiesfocus.com/2017/09/17/10509-shares-in-celgene-corporation-celg-purchased-by-berson-corrado-investment-advisors-llc.html.

Shares of Celgene Corporation (NASDAQ CELG) traded up 1.02% during midday trading on Friday, hitting $142.04. 5,983,997 shares of the company traded hands. The stock has a market capitalization of $111.12 billion, a P/E ratio of 43.99 and a beta of 1.89. The company has a 50-day moving average price of $134.97 and a 200-day moving average price of $127.46. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $142.69.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. Celgene Corporation’s revenue was up 18.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.44 EPS. Analysts anticipate that Celgene Corporation will post $7.33 earnings per share for the current fiscal year.

Several research firms have issued reports on CELG. Bank of America Corporation restated a “buy” rating on shares of Celgene Corporation in a research report on Wednesday. Jefferies Group LLC restated a “buy” rating and set a $160.00 price target on shares of Celgene Corporation in a research report on Friday. Cowen and Company restated a “buy” rating and set a $150.00 price target on shares of Celgene Corporation in a research report on Tuesday, September 12th. Royal Bank Of Canada began coverage on shares of Celgene Corporation in a research report on Thursday. They set a “top pick” rating and a $176.00 price target for the company. Finally, Mizuho upped their price target on shares of Celgene Corporation from $134.00 to $158.00 and gave the company a “buy” rating in a research report on Friday. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the stock. Celgene Corporation presently has an average rating of “Buy” and an average target price of $149.34.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply